• First biological product launched in 1999 with 4 holding the largest market share in China.
• Focusing on research and commercialization of recombinant protein drugs from prokaryotic expression and mammalian cell expression.
• Robust pipeline comprising of biosimilars and innovative biologics.
• Manufacturing facilities complying with cGMP requirements.
• Dosage forms: ampoules, vials, pre-filled syringes, etc.
• In accordance with the cGMP requirements of USFDA, EMA and NMPA.
• Manufacturing facilities are available for production of:
- Mammalian cell expression products
- Prokaryotic cell expression products
Qilu Biopharmaceutical Industrial Park